| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |